1
|
Li S, Zhuang S, Heit A, Koo SL, Tan AC, Chow IT, Kwok WW, Tan IB, Tan DS, Simoni Y, Newell EW. Bystander CD4 + T cells infiltrate human tumors and are phenotypically distinct. Oncoimmunology 2022; 11:2012961. [PMID: 36524209 PMCID: PMC9746624 DOI: 10.1080/2162402x.2021.2012961] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Tumor-specific T cells likely underpin effective immune checkpoint-blockade therapies. Yet, most studies focus on Treg cells and CD8+ tumor-infiltrating lymphocytes (TILs). Here, we study CD4+ TILs in human lung and colorectal cancers and observe that non-Treg CD4+ TILs average more than 70% of total CD4+ TILs in both cancer types. Leveraging high dimensional analyses including mass cytometry, we reveal that CD4+ TILs are phenotypically heterogeneous, within each tumor and across patients. Consistently, we find different subsets of CD4+ TILs showing characteristics of effectors, tissue resident memory (Trm) or exhausted cells (expressing PD-1, CTLA-4 and CD39). In both cancer types, the frequencies of CD39- non-Treg CD4+ TILs strongly correlate with frequencies of CD39- CD8+ TILs, which we and others have previously shown to be enriched for cells specific for cancer-unrelated antigens (bystanders). Ex-vivo, we demonstrate that CD39- CD4+ TILs can be specific for cancer-unrelated antigens, such as HCMV epitopes. Overall, our findings highlight that CD4+ TILs can also recognize cancer-unrelated antigens and suggest measuring CD39 expression as a straightforward way to quantify or isolate bystander CD4+ T cells.
Collapse
Affiliation(s)
- Shamin Li
- Fred Hutch Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, Washington, USA
| | - Summer Zhuang
- Fred Hutch Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, Washington, USA
| | - Antja Heit
- Fred Hutch Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, Washington, USA
| | - Si-Lin Koo
- Department of Anatomical Pathology, Singapore General Hospital, Singapore,Division of Medical Oncology, National Cancer Centre Singapore (NCCS), Singapore, Singapore
| | - Aaron C. Tan
- Division of Medical Oncology, National Cancer Centre Singapore (NCCS), Singapore, Singapore
| | - I-Ting Chow
- Agency for Science Technology and Research (A*Star), Genome Institute of Singapore (GIS), Singapore, Singapore
| | - William W. Kwok
- Agency for Science Technology and Research (A*Star), Genome Institute of Singapore (GIS), Singapore, Singapore
| | - Iain Beehuat Tan
- Department of Anatomical Pathology, Singapore General Hospital, Singapore,Division of Medical Oncology, National Cancer Centre Singapore (NCCS), Singapore, Singapore
| | | | - Yannick Simoni
- Fred Hutch Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, Washington, USA,Université de Paris, Institut Cochin INSERM U1016, Paris, France,CONTACT Yannick Simoni Université de Paris, Institut Cochin INSERM U1016, 22 Rue Mechain, Paris75014, France
| | - Evan W. Newell
- Fred Hutch Cancer Research Center, Vaccine and Infectious Disease Division, Seattle, Washington, USA,Evan W. Newell Fred Hutch Cancer Research Center, Vaccine and Infectious Disease Division, 1100 Fairview Ave. N., Mail Stop S2-204, Seattle, WA98109, USA
| |
Collapse
|